IL1B and myeloproliferative disorder: Both genetic knockout and pharmacological inhibition (by blocking antibodies) of IL-1β ameliorates the fibrotic phenotype of JAK2V617F MPN mice, the latter treatment also synergizing with ruxolitinib [14].